Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated ...
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Transaction value based on SEC Form 4 weighted average purchase price ($40.52); post-transaction value is $0.00 as Fitzpatrick held no shares after the transaction. Following the sale, Fitzpatrick ...
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Reducing total indirect ownership to 3,561,655 shares. All shares were disposed via indirect ownership through OrbiMed Private Investments VIII, LP; no direct holdings before or after the sale. Sell ...
Sionna Therapeutics, Inc. ( (SION)) has released its Q3 earnings. Here is a breakdown of the information Sionna Therapeutics, Inc. presented to its investors. Sionna Therapeutics, Inc. is a ...
NVIDIA is open-sourcing its Aerial software to accelerate AI-native 6G development, providing researchers with powerful tools on the NVIDIA DGX Spark platform, according to NVIDIA. NVIDIA is set to ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Sionna Therapeutics is defying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results